<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2151">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03078881</url>
  </required_header>
  <id_info>
    <org_study_id>AT342-01</org_study_id>
    <nct_id>NCT03078881</nct_id>
  </id_info>
  <brief_title>Clinical Assessment Study in Crigler-Najjar Syndrome</brief_title>
  <acronym>LUSTRO</acronym>
  <official_title>LUSTRO: A Clinical Assessment Study in Crigler-Najjar Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Audentes Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Audentes Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Pre-Phase 1 prospective, non-interventional clinical assessment study to evaluate
      Crigler-Najjar syndrome subjects requiring daily phototherapy, aged 1 year and older.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the disease course and natural history of subjects with Crigler-Najjar syndrome</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess variation in bilirubin levels over the course of the study and the variation of bilirubin levels over a 24-hr period</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess phototherapy usage over the course of the study</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the humanistic and clinical burden of disease in Crigler-Najjar subjects and caregivers as measured by PedsQL</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Crigler-Najjar Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll Crigler-Najjar syndrome subjects aged equal or greater than 1 year
        of age requiring daily phototherapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subject has a diagnosis of Crigler-Najjar syndrome resulting from a confirmed
             mutation in the UGT1A1 gene

          -  Subject is aged equal or greater than 1 year of age

          -  Subject receives daily phototherapy for a minimum of 6 hours within a 24-hour period
             (daily illumination time)

        Exclusion Criteria:

          -  Subject is currently participating in an interventional study or has received gene or
             cell therapy

          -  Subject has received a whole liver, partial liver, or hepatocyte transplant; or
             subject has a liver transplant scheduled within the planned participation period of
             this study

          -  Subject has significant cholestatic disease, in the opinion of the investigator

          -  Subject is receiving phenobarbital or other known inducer of UGT1A1 within 30 days of
             screening

          -  Subject has any clinically significant underlying liver disease (other than
             Crigler-Najjar syndrome), in the opinion of the investigator

          -  Subject has a history of, or currently has, a clinically important condition other
             than Crigler-Najjar syndrome, in the opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suyash Prasad, MBBS, MRCP,MRCPCH, FFPM</last_name>
    <role>Study Director</role>
    <affiliation>Audentes Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginia Casadas</last_name>
    <email>VCasadas@Audentestx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital at Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadia Ovchinsky, MD, MBA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The New York and Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mercedes Martinez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathleen M Loomes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic for Special Children</name>
      <address>
        <city>Strasburg</city>
        <state>Pennsylvania</state>
        <zip>17579</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin A Strauss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anil Dhawan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 13, 2017</lastchanged_date>
  <firstreceived_date>March 8, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Crigler-Najjar Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
